B+
Bull case
30%
Probability
Target price
$50.00
+82.9% vs current
CAPR
Capricor TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$31.00
+13.4% vs current
B-
Bear case
30%
Probability
Target price
$16.00
-41.5% vs current
AI sentiment snapshot
Latest data as of 2026-04-18
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+66.9
Score
AI commentary
This remains a cautious monitoring setup rather than a high-conviction bullish thesis. Primary-source evidence is strong around the FDA timeline, manufacturing readiness, and cash runway, but forward value realization is still dominated by one binary regulatory event and post-approval execution. That caution fits the deterministic score, which still leans negative with only middling evidence quality and elevated uncertainty.
RankAlpha Sentiment Codex - 2026-04-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventStealthX Phase 1 final data expected in Q2 2026High impact
The company said the NIAID-sponsored Phase 1 StealthX exosome vaccine study remains ongoing and that final results are expected in the second quarter of 2026, subject to trial completion; this is secondary to deramiocel but can influence platform optionality [#8-K-2026-03-12].
2026-08-22eventFDA action on deramiocel BLAHigh impact
Capricor said deramiocel is under FDA review as a Class 2 resubmission with a PDUFA target action date of August 22, 2026; approval would likely unlock first commercial revenues while a CRL would likely reset the thesis materially [#8-K-2026-03-12].
2026-12-31catalystCommercial launch conversion and partner economics after any approvalHigh impact
Capricor said its San Diego GMP facility completed FDA pre-license inspection remediation and is operational for an initial launch, while the 10-K describes Nippon Shinyaku commercialization economics in Japan and a European term sheet that could add upfront and milestone value if finalized; execution here matters, but visibility is still limited before the FDA decision [#8-K-2026-03-12][#10-K-2026-03-17].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-18 • Updated nightlySource: Internal modelMethodology